SeekIn Inc. announces the launch of OncoGraph, an innovative blood test designed to deliver scalable, patient-specific cancer monitoring powered by protein tumor markers (PTMs), signifying a new milestone in accessible oncology care.
Solution Overview
OncoGraph offers a tailored approach for tracking cancer recurrence and treatment response by identifying abnormally elevated PTMs for each patient and monitoring their longitudinal dynamics. Unlike traditional circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assays, which are costly and technically complex, OncoGraph provides an affordable and clinically actionable solution that is especially valuable for low- and middle-income countries (LMICs).
Clinical Impact
The OncoGraph method has been validated in studies involving liver cancer, lung cancer, and lymphoma patients. In liver cancer, OncoGraph-positive patients experienced higher recurrence rates and shorter recurrence-free survival after surgery. For advanced lung cancer, a significant decrease in PTMs following therapy was associated with longer progression-free survival. In lymphoma, PTM-based OncoGraph monitoring matched PET/CT results in assessing treatment response, underscoring its reliability and clinical equivalence to more expensive imaging modalities.
Accessibility and Scalability
By leveraging widely available and inexpensive PTMs, such as AFP, CA125, CEA, and CYFRA21-1, OncoGraph overcomes the limitations of disease-specific marker applicability through patient-specific selection. Its low cost and simple technical requirements enable widespread adoption in resource-limited healthcare systems.
Learn More
OncoGraph is now available for research and clinical deployment. For more information about OncoGraph, contact SeekIn Inc. at info@seekincancer.com.